Showing 3171-3180 of 5910 results for "".
- Optos Unveils MonacoPro Ultra-Widefield and OCT Retinal Imaging Technologyhttps://modernod.com/news/optos-unveils-monacopro-ultra-widefield-and-oct-retinal-imaging-technology/2482688/Optos announced the launch of MonacoPro, the next generation ultra-widefield (UWF) SLO and spectral domain retinal imaging solution. Building on the legacy of Monaco, Optos said MonacoPro introduces features designed to elevate diagnostic precision and streamline workflow for eye care profes
- Adverum Initiates ARTEMIS Phase 3 Study to Evaluate Ixo-vec for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-initiates-artemis-phase-3-study-to-evaluate-ixo-vec-for-wet-amd/2482686/Adverum Biotechnologies announced the initiation of ARTEMIS phase 3 study to evaluate Ixo-vec gene therapy (ixoberogene soroparvovec) as a one-time intravitreal (IVT) injection for neovascular (wet) age-related macular degeneration (AMD). Wet AMD is a leading cause of blindness in the e
- Mount Sinai Team Identifies Underlying Mechanisms of Age-Related Meibomian Gland Dysfunction, Possible Treatment Options for Dry Eye Diseasehttps://modernod.com/news/mount-sinai-team-identifies-underlying-mechanisms-of-age-related-meibomian-gland-dysfunction-possible-treatment-for-dry-eye-disease/2482679/New research from Mount Sinai identifies an underlying molecular mechanism of age-related degeneration in the meibomian glands essential to normal eye function. Now, this may lead to new therapeutic approaches for common conditions in older adults such as evaporated dry eye disease.
- Call for Nominations: Prevent Blindness Seeks to Honor Leaders in Vision Healthhttps://modernod.com/news/call-for-nominations-prevent-blindness-seeks-to-honor-leaders-in-vision-health/2482661/Prevent Blindness, one of the nation’s largest eye health and safety nonprofit organizations, issued their call for nominations for the “
- TECLens Secures $9.3 Million Series A Funding to Advance Its Noninvasive Refractive Technologyhttps://modernod.com/news/teclens-secures-93-million-series-a-funding-to-advance-its-noninvasive-refractive-technology/2482658/TECLens announced it raised $9.3 million in a Series A round to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. The funding round was co-led by Johnson &
- CooperVision Names Steven Robins as President, Americashttps://modernod.com/news/coopervision-names-steven-robins-as-president-americas/2482633/CooperVision has appointed Steven Robins as President, Americas, effective immediately. He has served for 3 decades in health care, with several high-profile corporate leadership and consulting roles in the vision care industry. Mr. Robins wa
- EMA Endorses Macustar's Work on Early AMD Clinical Trialshttps://modernod.com/news/ema-endorses-macustars-work-on-early-amd-clinical-trials/2482631/The European Medicines Agency (EMA) has issued its third 'Letter of Support' to the Macustar consortium, a European public-private partnership focused on advancing clinical trial methodologies for early-stage age-related macular degeneration (AMD). This endorsement follows the consortium&
- Hoya Vision Care Expands MiYOSMART Power Range for High Myopia Treatment in Childrenhttps://modernod.com/news/hoya-vision-care-expands-miyosmart-power-range-for-high-myopia-treatment-in-children/2482630/Hoya Vision Care announced the launch of an extended power range for its MiYOSMART spectacle lenses, offering a new solution for children suffering from high myopia. Designed specifically to address the needs of high myopic patients, the new lenses feature a broader range of prescriptions, slimme
- Prevent Blindness Receives Legacy Donation of $9.7 Million, Largest in Historyhttps://modernod.com/news/prevent-blindness-receives-legacy-donation-97-million-largest-in-history/2482622/Prevent Blindness announced it has received a donation of $9.7 million from the Estate of Pamela Behrens, a Florida resident and previous donor. Founded in 1908, this is the largest donation the organization has ever received. Ms. Behrens made the donation in honor of her late hus
- Aviceda Therapeutics Raises $207.5 Million to Advance Lead Program AVD-104 for Geographic Atrophy into Phase 3 Testinghttps://modernod.com/news/aviceda-therapeutics-raises-2075-million-to-advance-lead-program-avd-104-for-geographic-atrophy-into-phase-3-testing/2482603/Aviceda Therapeutics announced the closing of a $207.5 million Series C financing to propel the company’s pivotal phase 3 clinical trial for AVD-104, a treatment candidate for geographic atrophy